This approach is still early in development, with preclinical results showing the tLNPs can effectively deliver mRNA encoding an anti-CD19 CAR to CD8+ T cells, leading to rapid and profound anti-tumor and anti-primary B cell activity in mice [195]. The gene discussed is CD8A; the disease is neoplasm.